The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Exactly Grape, As I said below. Quite remarkable! We got both legs broken , but hey we are up and about on newsflow crutches and everyone is cheering. Lol It's the best of a bad lot, is what it is and good to have to save falling further. Could it be news wrt a placing ?
Unbelievable after all this time now Premaitha starts banging RNS's out with approx figures and approx revenue figures! finally !!! Funny how all of a dudden all this news is coming out so fast lol... Anyway it is all welcome and time to get back on track so well done Premaitha on these miraculous contracts you have all of a sudden found! GLA
I am still very disappointed at court loss being so one sided versus our rhetoric and expectations . not really even a mixed result that favoured illumina. Just a beating!
Bought 80,000. This newsflow must have been held to build upon expected court victory and now comes tumbling out to support . we went from 8p to 4p and up to 5p on 2 rns. Anyone would think think we'd won the lottery! This remains very disappointing and this news is needed to stop further falls and weakening sentiment . Seems to be working and that's good, but all the euphoria at five pence if we hold it after newsflow reverts to usual.
The revenues seem bit light given that the number of tests and I think are more than the UK. The number of tests according to Hardman Sep 17 (discredited) of H1 2017 was 22,000 tests vs 11,000 is H1 2016. So the volume is very significant. Maybe they're being pessimistic. The point I think they're making which we should receive is the UK market can be replaced with the existing pipeline.
Stupidly cheap at these prices. Four labs mid east cover the revenues they get from the UK!
panels even
The 'other diagnostic Pamela's is why I have stayed here this long. With nipt shortly turning a profit the additional products (cancer screening?) will turn us into a far bigger player and target for TF
' generating in excess of �0.6 million in annual revenues for the Company; and substantial revenues for its equipment partners'. A not so subtle nod to our main 'investor' and possible future owner? Anyway hopefully another income stream to keep the wolf from the door until the litigation is sorted one way or the other.
Good to see some numbers but £50 a test seems lower than normal?
very good hopefully see the recovery continue
They are expanding fast :-)
'Premaitha anticipates these four laboratories will perform an aggregate volume of over 12,000 NIPT tests per year ' Look at the numbers...Same numbers as their UK arm of the business perform !!!!
not only further ME expansion but also "...other diagnostic panels we are currently developing". Looking good short, medium and long term imo.
whilst they lost the case regards the technicalities(pending appeal) of the patents, I believe they have a stronger case regards anti-trust etc. This was demonstrated by Illumina and their actions against GOSH (amongst others)which I reckon will come back to haunt them!
the only thing I am interested in is will the company survive, and I think it certainly will! I know some moaned like feck about postponing the trial but what would have happened if we had taken them on at that time and lost?? At least it gave them time to go global!
Agreed notaflipper. If there is an appeal the EU commission will come to a anti competition conclusion before the UK appeal is over. Illumina would be keen to be viewed as being fair in any license​ agreement with Premaitha. Can see this being 8p before the results as alot of the bad news was already priced in at that point. With damages limited to £2m if no agreement is reached and the non UK business doing extremely well, these prices are a buy imo
Now that the share price has stabalised and the outline of a potential settlement and bounds of any damages are increasingly becoming clearer (thanks bakky) we may find new fellow investors in the next week. So our resident expert will be joined by many who will never tire of telling us of their great entry price. Much of what was said in this post was fair. They're I'm sure many LTH's who despite feeling misinformed and let down by the BoD will still be averaging down next week. This may be a slow ride to 2015 levels as with a low entry point there will have to be a constant supply of good news to resupply the inevitable churn of investors. Hopefully however there's more RNS next week which could secure a strong bounce. I suspect the BoD know the urgency of this. With Interim results due within 2-3 weeks we should seen further news and a lifting of the moratorium on Director share purchases. Key thing of the week is no Press Release from St George or any other NHS trust or private clinic distancing themselves from the IONA test, no Institutional sales and no Director sales.
As usualt , twix it is difficult to follow the logic of your arguement , most are or were in VIY and NIPT to make money , not waffle ...........frankly you seem to lose credibility as time ( and posts ) go on .....
I think generally what has happened here so far as we investors are concerned is that the company and all related (which means tw and most of us not always me haha) are predisposed to looking at everything in the best light just as it is ALWAYS presented. Not much critical thinking. So, for instance comfort is taken from tw comment on likely maximum for costs . Nobody can know the fallout and figures or the financial damage that the injunctive relief may bring and of course the best spin is issued by the company, but we know expectations are seldom met so far on delivery or time frames. All said, at this price one has to agree that it's a buy and for those of us who keep thinking buying opportunities will dry up at each current low. Whereas they have just got better and better, for years ! Lol I will buy a few more in this latest sale. Grrrrrr I do wish, if our bod want to paint a positive and reassuring picture, that much more often it better stood up to critical thinking and above all came to pass more often than not. Imv this track record is woefull.
reply from Prem to a few questions ; The company commissioned a freedom to operate opinion at the time of listing and its legal advice throughout has been that of a good chance of success. However, these are complex, ground-breaking legal and technical matters and trials are unfortunately unpredictable. The EU Competition Commission�s investigation into potentially anticompetitive conduct is ongoing and the company believes it should conclude within the appeal timeframe. They would not rule on whether the patents are valid or whether Premaitha infringes them, but they could impose significant penalties and enforce compulsory licensing of the patents. 'The first instance judgment does not affect whether the court would consider Premaitha's competition law defence after the patent hearings. The company will provide further information regarding this when the patent proceedings are further advanced. The first instance judgment�s effect is limited to the UK and under UK law any damages cannot be �punitive� but solely compensatory for losses that must be proven'.
Latest partner is believed to be in South Korea.
This is worth multiple of the current price. I'm buying heavily at these prices
'After the Illumina legal setback for Premaitha (NIPT) we suggested that the cost of that setback was very manageable � a maximum of less than �2 million is what we hear � and that the underlying business is doing very well. That view is reaffirmed by latest news'.
CONFIDENTIALITY Shooooosh mums the word........reminds me of a share I had.